Table 3 Safety outcomes: Bayesian random-effects network meta-analysis of switching and non-switching arms of biosimilars and reference biologics drugs for arthritis rheumatoid.

From: Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis

Safety outcomes

Serious TEAE

 TEAE

Bios → Bios

0.882 (0.461, 1.542)

1.171 (0.739, 1.901)

2.020 (0.627, 5.515)

0.921 (0.772, 1.104)

Ref → Ref

1.032 (0.537, 1.852)

1.796 (0.524, 4.495)

1.082 (0.949, 1.233)

0.996 (0.826, 1.203)

Ref→Bios

1.729 (0.526, 4.707)

1.126 (0.734, 1.661)

1.035 (0.678, 1.547)

1.039 (0.675, 1.552)

Bios→Ref

 IRRs

 

 Hypersensitivity

Bios → Bios

1.032 (0.334, 3.216)

0.822 (0.336, 2.038)

N/A

0.914 (0.183, 4.177

Ref → Ref

0.847 (0.262, 2.848)

N/A

0.727 (0.087, 3.442)

0.657 (0.079, 3.089)

Ref→Bios

N/A

N/A

N/A

N/A

Bios→Ref

 Serious Infections

 Malignancies

Bios → Bios

1.809 (0.442, 6.200)

1.286 (0.680, 2.744)

N/A

0.783 (0.161, 3.136)

Ref → Ref

1.809 (0.442, 6.200)

N/A

1.078 (0.337, 3.361)

0.847 (0.162, 3.447

Ref→Bios

N/A

N/A

N/A

N/A

Bios→Ref

 Discontinuation rates

Bios → Bios

N/A

N/A

N/A

1.176 (0.869, 1.574)

Ref → Ref

N/A

N/A

0.931 (0.748, 1.152)

1.094 (0.787, 1.500)

Ref→Bios

N/A

0.603 (0.264, 1.234)

0.707 (0.307, 1.463)

0.648 (0.284, 1.338)

Bios→Ref

  1. Abbreviations in italics represent non-switching arms and switching arms. The values given are RR [95% CrIs]) for binary outcomes, in which RR greater than 1 favors the arm in the column.
  2. Ref-Ref: patients taking reference biologics drugs continued the treatment (non-switching group); Bios-Bios: patients taking biosimilars continued the treatment (non-switching group); Ref-Bios: patients taking reference biologics drugs switched to biosimilars (switching group); Bios-Ref: patients taking biosimilars switched to reference biologics drugs (switching group). TEAEs: treatment-emergent adverse events; IRRs: infusion-related reactions; RR: relative risk; CrI: credible intervals; N/A: not available.
Back to article page